



Sanofi Pasteur Launches Pentaxim[®], First 5-in-1 Combination Vaccine in China

New vaccine Pentaxim[®] reduces infant shots from twelve to four

Lyon, France - May 11, 2011 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY) launched today Pentaxim[®], the first 5-in-1 combination vaccine in China to immunize against diphtheria, tetanus, pertussis, polio and *Haemophilus influenzae* type b. The debut of the first 5-in-1 combination vaccine was celebrated with over 200 Chinese and international experts and hailed as the beginning of a new era in the immunization field in China. In order to facilitate the adoption of the new combination vaccine for the benefit of consumers, the Chinese Preventive Medicine Association (CPMA) introduced a first-of-its-kind technical guideline for doctors at Points of Vaccination.

Pentaxim[®] (DTaP-IPV-Hib) vaccine was first marketed in 1997. To date, more than 100 million doses of Pentaxim[®] have been distributed in over 100 countries, and the vaccine has been included in the national immunization programs in 23 countries. Pentaxim[®] vaccine is the first acellular pertussis pentavalent vaccine in China against five deadly childhood diseases. It reduces the number of shots from twelve to four, and achieves the same level of protection as immunized with single-antigen vaccines.

The launch of Pentaxim[®] vaccine comes just eighteen months after Sanofi Pasteur introduced the first and only Inactivated Poliomyelitis Vaccine (IPV) to China. It also adds to a long list of innovative vaccines that Sanofi Pasteur has brought to the country, including the first rabies vaccine, the first influenza vaccine and the first Hib vaccine.

Presiding over the launch ceremony, Christopher A. Viehbacher, Chief Executive Officer of Sanofi, said: *"We are truly excited and proud to bring the first 5-in-1 combination vaccine to China, and we are greatly encouraged by the confidence and support of immunization experts in China. Over a century after Louis Pasteur invented the world's first rabies vaccine, Sanofi Pasteur remains committed to its vision which is a world in which no one suffers or dies from a vaccine-preventable disease."*

Experts pointed out that, in addition to less shots for infants and greater comfort for parents, the new 5-in-1 (DTaP-IPV-Hib) combination vaccine ensures better compliance with the vaccination schedule. Fewer shots also mean time saved for parents and more efficiency at points of vaccination.

Professor Shen Xuzhuang from Beijing Children's Hospital commented, *"The launch of the first 5-in-1 combination vaccine supports the shared commitment of the Chinese government and the scientific community to enhance preventive healthcare. Vaccination remains the only effective way to prevent infectious diseases, and combination vaccines are clearly the future trend of vaccine development because of greater convenience, comfort and safety."*



About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contact:

Global Media Relations

Pascal Barollier
T. +33-(0)4-37-37-50-38
pascal.barollier@sanofipasteur.com
www.sanofipasteur.com